About: Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article by Pierre Théroux et al published 4 May 2005 in European Heart Journal

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2005 (uk) im Mai 2005 veröffentlichter wissenschaftlicher Artikel (de) 2005 മെയ് 4നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്രീയ ലേഖനം (ml) article by Pierre Théroux et al published 4 May 2005 in European Heart Journal (en)
publication date	wds:Q57484297-97533690-C910-487D-9432-1BEA8E9B969D
publication date	2005-05-04 00:00:00Z (xsd:dateTime)
author name string	wds:Q57484297-05C05071-8101-4CEB-BDD5-C9A3BB0D218E wds:Q57484297-080D4BC5-4A52-4B9E-A636-F9262FAE93B5 wds:Q57484297-14A68975-56D6-4F2F-AF3D-05C097B93CEC wds:Q57484297-216D7A39-B33E-4EE6-A1EE-BB321DC90D6B wds:Q57484297-5B3EC476-CB41-41CE-A695-C82345C3BC57 wds:Q57484297-7F431AB0-7A15-4B85-9B72-A360DFE871AC wds:Q57484297-9155F3FA-5A44-493F-AEDC-3560C2953509 wds:Q57484297-9718BD6A-3325-4B45-BB4F-FDCB7C290C57 wds:Q57484297-F7845A7C-8F06-4B5E-9DB7-375ACBF3C03B
author name string	Pierre Théroux Joel Lavoie The Minh Luong Paul W. Armstrong Judith S. Hochman Jose C. Nicolau Scott Rollins Kevin J. Malloy Jeb Burchenal
rdfs:label	Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (en) Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (nl)
skos:prefLabel	Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (en) Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (nl)
name	Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (en) Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (nl)
author	wds:Q57484297-4B5A4048-9E79-4FFD-ADBE-6124666C6CA6 wds:Q57484297-AD9754FF-A47D-4218-A032-5A7D5768610E
author	Kenneth W Mahaffey Christopher B. Granger
title	wds:Q57484297-68C0EF04-329C-480C-A41A-7171C1392660
title	Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial (en)
page(s)	wds:Q57484297-229FBCDF-CD6D-48F3-88E4-DF80A49A92C8
page(s)	1964-1970
instance of	wds:Q57484297-4F82AACA-8EF1-47C5-AFB8-FE65846E9C5B
instance of	scholarly article
main subject	wds:Q57484297-50CA2A6A-B8EC-49FE-9113-53F48D5FD9AC wds:Q57484297-692FD607-4074-4A7F-9896-459CC522E3E1 wds:Q57484297-BCF7812E-5AFF-4C82-B309-D7AA127C918D wds:Q57484297-BFC39BF4-C5BD-495C-98E9-0CD11FCDD75D
main subject	inflammation myocardial infarction angioplasty Patients
PubMed ID	wds:Q57484297-7AC9C6C9-5C99-4DCA-BE58-A53C382EB620
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15872036
PubMed ID	15872036
published in	wds:Q57484297-1257486F-7D0D-4A86-963E-BC5546EF26AF
published in	European Heart Journal
issue	wds:Q57484297-1AF0EFDD-9B9E-4B39-8F80-8C74401A7B69
volume	wds:Q57484297-90C1C200-A723-4D09-B149-C8D55B24E4FA
issue	19
volume	26
DOI	wds:Q57484297-27E94486-6BEF-4E88-BF70-A898143650B1
DOI	http://dx.doi.org/10.1093/EURHEARTJ/EHI292
DOI	10.1093/EURHEARTJ/EHI292
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57484297
is cites work of	Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size. Causes of death and re‐hospitalization in cardiogenic shock Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention Cardiogenic shock: the role of inflammation On the value of therapeutic interventions targeting the complement system in acute myocardial infarction Inflammation and reduced endothelial function in the course of severe acute heart failure Elevation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in patients presenting with acute myocardial infarction Complement activity and pharmacological inhibition in cardiovascular disease Benefits of Intraaortic Balloon Support for Myocardial Infarction Patients in Severe Cardiogenic Shock Undergoing Coronary Revascularization Effect of inflammatory factor-induced cyclo-oxygenase expression on the development of reperfusion-related no-reflow phenomenon in acute myocardial infarction. Interleukin-6 may predict survival in extracorporeal membrane oxygenation treatment. IL-6 signalling in patients with acute ST-elevation myocardial infarction Management of acute myocardial infarction Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock Inflammatory markers in ST-elevation acute myocardial infarction Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-γ, TNF-α, MIP-1β, G-CSF, and MCP-1β. Predicting the no-reflow phenomenon following successful percutaneous coronary intervention. Tissue necrosis factor α and targeting its receptor in ischaemic heart disease Inflammatory Cytokines Imbalance in the Very Early Phase of Acute Coronary Syndrome: Correlations with Angiographic Findings and In-Hospital Events Management of cardiogenic shock complicating acute myocardial infarction: A review Clinical implications of cytokines in the critical-care unit TNF-α, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. Anticomplement therapy. Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? Cardiogenic shock elicits acute inflammation, delayed eosinophilia, and depletion of immune cells in most severe cases Established and novel biomarkers in ST-elevation myocardial infarction Human C5-specific single-chain variable fragment ameliorates brain injury in a model of NMOSD No-reflow reversibility: a study based on serial assessment of multiple biomarkers Vascular phenotypes of acute decompensated vs. new-onset heart failure: treatment implications. Therapeutic strategies for cardiogenic shock, 2006
is cites work of	wds:Q38799021-EDAC3D05-45DA-476C-9B32-21C471AFBF7F wds:Q42256397-7902A9CF-9B20-407E-A192-A51C31D43E24 wds:Q46092121-EE52CBBD-874B-473E-A6F6-CBA73E06C142

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software